BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 31090071)

  • 1. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
    Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
    J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma.
    Arai D; Hegab AE; Soejima K; Kuroda A; Ishioka K; Yasuda H; Naoki K; Shizuko K; Hamamoto J; Yin Y; Ornitz DM; Betsuyaku T
    J Pathol; 2015 Mar; 235(4):593-605. PubMed ID: 25413587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms.
    Hegab AE; Ozaki M; Kagawa S; Hamamoto J; Yasuda H; Naoki K; Soejima K; Yin Y; Kinoshita T; Yaguchi T; Kawakami Y; Ornitz DM; Betsuyaku T
    Lung Cancer; 2018 May; 119():25-35. PubMed ID: 29656749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
    Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
    Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis.
    Kato N; Iwase A; Ishida C; Nagai T; Mori M; Bayasula ; Nakamura T; Osuka S; Ganiyeva U; Qin Y; Miki R; Kikkawa F
    Reprod Sci; 2019 Jul; 26(7):979-987. PubMed ID: 30270745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
    Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
    Maehara O; Suda G; Natsuizaka M; Ohnishi S; Komatsu Y; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Shimazaki T; Kimura M; Asano A; Fujimoto Y; Ohashi S; Kagawa S; Kinugasa H; Naganuma S; Whelan KA; Nakagawa H; Nakagawa K; Takeda H; Sakamoto N
    Carcinogenesis; 2017 Oct; 38(11):1073-1083. PubMed ID: 28927233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
    Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
    Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
    Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
    Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
    Giri D; Ropiquet F; Ittmann M
    Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of FGF9 and NOVA1 in cancer-associated fibroblasts promotes cell proliferation, invasion and migration of triple negative breast cancer.
    Zhang B; Liu Y; Yu J; Lin X
    Drug Dev Res; 2024 May; 85(3):e22185. PubMed ID: 38657094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
    Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD
    Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.